Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.1
3.0
Journals
Antibodies
Special Issues
Review Collection on Humoral Immunity
share announcement

Review Collection on Humoral Immunity

A special issue of Antibodies (ISSN 2073-4468). This special issue belongs to the section "Humoral Immunity".

Deadline for manuscript submissions: closed (31 July 2024) | Viewed by 3212

Special Issue Editors

Prof. Dr. Jagadeesh Bayry

E-Mail Website
Guest Editor
Centre de Recherche des Cordeliers, Sorbonne Université, F-75006 Paris, France
Interests: immunology; immune homeostasis; immunotherapy; host-pathogen interaction
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Linqi Zhang

E-Mail Website
Guest Editor
Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing 100084, China
Interests: antibody; vaccine; viruses

Special Issue Information

Dear Colleagues,

The “Humoral Immunity” Section is devoted to publishing major advancements related to the antibody response in a wide variety of host species under physiological, pathological, therapeutic, and vaccination conditions. The main topics include, but are not limited to, the following:

  1. Antibody response during infections, diseases, treatments, and vaccination;
  2. Identification and evaluation of biomarkers associated with antibody production and protection;
  3. Neutralizing antibodies against pathogens and toxins;
  4. Self-reactive autoantibodies;
  5. Structure and function of clinically relevant antibodies;
  6. Physiological antibody generation as well as maturation and related mechanisms, such as antigen presentation for B cell activation, cytokine production, germinal center formation, isotype switching, affinity maturation, and long-term memory generation;
  7. Mechanisms of and interference with antibody-mediated complement activation.

In particular, we welcome submissions exploring the use of cutting-edge technologies across disciplines to provide a comprehensive overview of the mechanisms of the humoral immune response during natural development, diseases, therapy, and vaccination.

Prof. Dr. Jagadeesh Bayry
Prof. Dr. Linqi Zhang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

15 pages, 3024 KiB  
Review
Allogeneic HLA Humoral Immunogenicity and the Prediction of Donor-Specific HLA Antibody Development
by Vadim Jucaud
Antibodies 2024, 13(3), 61; https://doi.org/10.3390/antib13030061 - 24 Jul 2024
Viewed by 342
Abstract
The development of de novo donor-specific HLA antibodies (dnDSAs) following solid organ transplantation is considered a major risk factor for poor long-term allograft outcomes. The prediction of dnDSA development is a boon to transplant recipients, yet the assessment of allo-HLA immunogenicity remains imprecise. [...] Read more.
The development of de novo donor-specific HLA antibodies (dnDSAs) following solid organ transplantation is considered a major risk factor for poor long-term allograft outcomes. The prediction of dnDSA development is a boon to transplant recipients, yet the assessment of allo-HLA immunogenicity remains imprecise. Despite the recent technological advances, a comprehensive evaluation of allo-HLA immunogenicity, which includes both B and T cell allorecognition, is still warranted. Recent studies have proposed using mismatched HLA epitopes (antibody and T cell) as a prognostic biomarker for humoral alloimmunity. However, the identification of immunogenic HLA mismatches has not progressed despite significant improvements in the identification of permissible mismatches. Certainly, the prediction of dnDSA development may benefit permissible HLA mismatched organ transplantations, personalized immunosuppression, and clinical trial design. However, characteristics that go beyond the listing of mismatched HLA antibody epitopes and T cell epitopes, such as the generation of HLA T cell epitope repertoires, recipient’s HLA class II phenotype, and immunosuppressive regiments, are required for the precise assessment of allo-HLA immunogenicity. Full article
(This article belongs to the Special Issue Review Collection on Humoral Immunity)
►▼ Show Figures

Figure 1

13 pages, 1159 KiB  
Review
A Comparison of Natural and Therapeutic Anti-IgE Antibodies
by Monique Vogel and Paul Engeroff
Antibodies 2024, 13(3), 58; https://doi.org/10.3390/antib13030058 - 16 Jul 2024
Viewed by 742
Abstract
Immunoglobulin E (IgE) plays a critical role for the immune system, fighting against parasites, toxins, and cancer. However, when it reacts to allergens without proper regulation, it can cause allergic reactions, including anaphylaxis, through a process initiated by effector cells such as basophils [...] Read more.
Immunoglobulin E (IgE) plays a critical role for the immune system, fighting against parasites, toxins, and cancer. However, when it reacts to allergens without proper regulation, it can cause allergic reactions, including anaphylaxis, through a process initiated by effector cells such as basophils and mast cells. These cells display IgE on their surface, bound to the high-affinity IgE receptor FcεRI. A cross-linking antigen then triggers degranulation and the release of inflammatory mediators from the cells. Therapeutic monoclonal anti-IgE antibodies such as omalizumab, disrupt this process and are used to manage IgE-related conditions such as severe allergic asthma and chronic spontaneous urticaria. Interestingly, naturally occurring anti-IgE autoantibodies circulate at surprisingly high levels in healthy humans and mice and may thus be instrumental in regulating IgE activity. Although many open questions remain, recent studies have shed new light on their role as IgE regulators and their mechanism of action. Here, we summarize the latest insights on natural anti-IgE autoantibodies, and we compare their functional features to therapeutic monoclonal anti-IgE autoantibodies. Full article
(This article belongs to the Special Issue Review Collection on Humoral Immunity)
►▼ Show Figures

Figure 1

17 pages, 1931 KiB  
Review
Beyond bNAbs: Uses, Risks, and Opportunities for Therapeutic Application of Non-Neutralising Antibodies in Viral Infection
by Kahlio Mader and Lynn B. Dustin
Antibodies 2024, 13(2), 28; https://doi.org/10.3390/antib13020028 - 3 Apr 2024
Viewed by 1670
Abstract
The vast majority of antibodies generated against a virus will be non-neutralising. However, this does not denote an absence of protective capacity. Yet, within the field, there is typically a large focus on antibodies capable of directly blocking infection (neutralising antibodies, NAbs) of [...] Read more.
The vast majority of antibodies generated against a virus will be non-neutralising. However, this does not denote an absence of protective capacity. Yet, within the field, there is typically a large focus on antibodies capable of directly blocking infection (neutralising antibodies, NAbs) of either specific viral strains or multiple viral strains (broadly-neutralising antibodies, bNAbs). More recently, a focus on non-neutralising antibodies (nNAbs), or neutralisation-independent effects of NAbs, has emerged. These can have additive effects on protection or, in some cases, be a major correlate of protection. As their name suggests, nNAbs do not directly neutralise infection but instead, through their Fc domains, may mediate interaction with other immune effectors to induce clearance of viral particles or virally infected cells. nNAbs may also interrupt viral replication within infected cells. Developing technologies of antibody modification and functionalisation may lead to innovative biologics that harness the activities of nNAbs for antiviral prophylaxis and therapeutics. In this review, we discuss specific examples of nNAb actions in viral infections where they have known importance. We also discuss the potential detrimental effects of such responses. Finally, we explore new technologies for nNAb functionalisation to increase efficacy or introduce favourable characteristics for their therapeutic applications. Full article
(This article belongs to the Special Issue Review Collection on Humoral Immunity)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop